Final Results of a Phase 3 European Study Demonstrate Aranesp(R) Dosed Once Every Three Weeks is at Least as Effective as Weekly Dosing in Treating Patients With Chemotherapy-Induced Anaemia
Stockholm, Sweden (ots/PRNewswire) - Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, announced that new data from a randomised, double-blind Phase 3 study demonstrate that Aranesp(r) (darbepoetin alfa) administered as a fixed dose of 500 mcg once every three weeks is at least as effective as ...
mehr